GSK plc

GSK plc EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of GSK plc (GSK.L) as of Nov 12, 2026 is 12.77 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 9.52 % — a change of 34.06% (higher).

EBIT/Assets

12.77 %

YoY

34.06%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of GSK plc is 2025 12.77 % . Operating Income to Assets Ratio (EBIT/Assets) of GSK plc was 2024 9.52 % . It decreases by 34.06% higher compared to the previous year.

The GSK plc EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
13.78 GBP
Jan 1, 2019
9.77 GBP
Jan 1, 2020
10.17 GBP
Jan 1, 2021
6.83 GBP
Jan 1, 2022
11.11 GBP
Jan 1, 2023
11.85 GBP
Jan 1, 2024
9.52 GBP
Jan 1, 2025
12.77 GBP
The GSK plc EBIT/Assets history
YEAREBIT/AssetsYoY
12.77 %+34.06%
9.52 %-19.66%
11.85 %+6.68%
11.11 %+62.59%
6.83 %-32.84%
10.17 %+4.17%
9.77 %-29.10%
13.78 %-2.60%
14.14 %+22.34%
11.56 %+38.50%
8.35 %-30.74%
12.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Operating Income to Assets Ratio (EBIT/Assets) of GSK plc is 12.77 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of GSK plc changed from 9.52 % to 12.77 %, representing a 34.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) GSK plc since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GSK plc

All Key Metrics — GSK plc